Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Should You Sell AEGON N.V. (ADR) (AEG)?

Page 1 of 2

Is it smart to be bullish on AEGON N.V. (ADR) (NYSE:AEG)?

In the 21st century investor’s toolkit, there are plenty of indicators investors can use to analyze their holdings. Two of the most useful are hedge fund and insider trading interest. At Insider Monkey, our studies have shown that, historically, those who follow the best picks of the top fund managers can trounce the broader indices by a significant margin (see just how much).

Equally as useful, positive insider trading sentiment is another way to look at the marketplace. There are lots of incentives for an executive to cut shares of his or her company, but just one, very obvious reason why they would buy. Many empirical studies have demonstrated the market-beating potential of this method if shareholders know what to do (learn more here).


Keeping this in mind, we’re going to discuss the latest info about AEGON N.V. (ADR) (NYSE:AEG).

Hedge fund activity in AEGON N.V. (ADR) (NYSE:AEG)

At the end of the second quarter, a total of 8 of the hedge funds we track were bullish in this stock, a change of 0% from one quarter earlier. With hedge funds’ capital changing hands, there exists a select group of noteworthy hedge fund managers who were upping their stakes significantly.

When using filings from the hedgies we track, Peter Rathjens, Bruce Clarke and John Campbell’s Arrowstreet Capital had the biggest position in AEGON N.V. (ADR) (NYSE:AEG), worth close to $28.1 million, accounting for 0.2% of its total 13F portfolio. Sitting at the No. 2 spot is Himanshu H. Shah of Shah Capital Management, with a $2.7 million position; 2.6% of its 13F portfolio is allocated to the company. Remaining hedge funds that hold long positions include Malcolm Fairbairn’s Ascend Capital, John Overdeck and David Siegel’s Two Sigma Advisors and Jim Simons’s Renaissance Technologies.

Because AEGON N.V. (ADR) (NYSE:AEG) has faced dropping sentiment from upper-tier hedge fund managers, we can see that there was a specific group of money managers that slashed their positions entirely at the end of the second quarter. At the top of the heap, Himanshu H. Shah’s Shah Capital Management dumped the biggest position of all the hedgies we key on, comprising close to $2.5 million in stock. David Costen Haley’s fund, HBK Investments, also sold off its stock, about $0.8 million worth. These moves are important to note, as total hedge fund interest stayed the same (this is a bearish signal in our experience).

What do corporate executives and insiders think about AEGON N.V. (ADR) (NYSE:AEG)?

Insider buying made by high-level executives is best served when the company we’re looking at has seen transactions within the past half-year. Over the latest half-year time period, AEGON N.V. (ADR) (NYSE:AEG) has seen zero unique insiders purchasing, and zero insider sales (see the details of insider trades here).

We’ll check out the relationship between both of these indicators in other stocks similar to AEGON N.V. (ADR) (NYSE:AEG). These stocks are Prudential Financial Inc (NYSE:PRU), Manulife Financial Corporation (USA) (NYSE:MFC), Torchmark Corporation (NYSE:TMK), Sun Life Financial Inc. (USA) (NYSE:SLF), and Lincoln National Corporation (NYSE:LNC). All of these stocks are in the life insurance industry and their market caps resemble AEG’s market cap.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!